| Stafford Adrian Preston, MD | |
|
44000 West Twelve Mile Road, Suite 200, Novi, MI 48377 | |
| (248) 347-8191 | |
| (248) 347-8110 |
| Full Name | Stafford Adrian Preston |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 40 Years |
| Location | 44000 West Twelve Mile Road, Novi, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023098597 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 4301019862 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension Providence Hospital, Southfield And Novi | Southfield, MI | Hospital |
| Ascension St John Hospital | Detroit, MI | Hospital |
| Huron Valley-sinai Hospital | Commerce township, MI | Hospital |
| St Joe Mercy Hospital System Livonia | Livonia, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ascension Providence Hospital | 6103738703 | 181 |
News Archive
University of Limerick researchers have been awarded €175,000 to undertake research which aims to improve diagnosis and management of delirium, dementia and depression among palliative care patients.
Post Co. said Monday it would buy a majority stake in Celtic Healthcare Inc., a closely held provider of hospice and home health care in Pennsylvania and Maryland. Terms of the deal weren't disclosed, although one analyst, Sheryl Skolnick of CRT Capital Group, said average valuations suggests the deal could have been worth at least $50 million. That is a drop in the bucket for Post Co., which has a market capitalization of $2.7 billion.
Vertex Pharmaceuticals (Australia) Pty Ltd., announces the presentation of data from KALYDECO (ivacaftor) studies at the 10th Australasian Cystic Fibrosis Conference in Auckland, New Zealand, August 17 – 20, 2013, which further demonstrate the benefits of the medicine in people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.
Pharmasset, Inc. announced today that the interim results from the PROPEL study conducted by its partner Roche demonstrate that RG7128 triple combination therapy was safe and well tolerated. In that study, the safety profile of RG7128 (1000mg BID or 500mg BID), when administered for 8 or 12 weeks with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin), the standard of care, was similar to the safety profile of SOC alone.
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial. Study AIR645-CS2 is a phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of inhaled AIR645 in suppressing the asthmatic response in subjects with mild asthma. Results are expected in the third quarter of 2010.
› Verified 8 days ago
| Entity Name | Ascension Providence Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942265236 PECOS PAC ID: 6103738703 Enrollment ID: O20031103000326 |
News Archive
University of Limerick researchers have been awarded €175,000 to undertake research which aims to improve diagnosis and management of delirium, dementia and depression among palliative care patients.
Post Co. said Monday it would buy a majority stake in Celtic Healthcare Inc., a closely held provider of hospice and home health care in Pennsylvania and Maryland. Terms of the deal weren't disclosed, although one analyst, Sheryl Skolnick of CRT Capital Group, said average valuations suggests the deal could have been worth at least $50 million. That is a drop in the bucket for Post Co., which has a market capitalization of $2.7 billion.
Vertex Pharmaceuticals (Australia) Pty Ltd., announces the presentation of data from KALYDECO (ivacaftor) studies at the 10th Australasian Cystic Fibrosis Conference in Auckland, New Zealand, August 17 – 20, 2013, which further demonstrate the benefits of the medicine in people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.
Pharmasset, Inc. announced today that the interim results from the PROPEL study conducted by its partner Roche demonstrate that RG7128 triple combination therapy was safe and well tolerated. In that study, the safety profile of RG7128 (1000mg BID or 500mg BID), when administered for 8 or 12 weeks with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin), the standard of care, was similar to the safety profile of SOC alone.
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial. Study AIR645-CS2 is a phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of inhaled AIR645 in suppressing the asthmatic response in subjects with mild asthma. Results are expected in the third quarter of 2010.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stafford Adrian Preston, MD 44000 W 12 Mile Rd, Suite 200, Novi, MI 48377 Ph: (248) 347-8191 | Stafford Adrian Preston, MD 44000 West Twelve Mile Road, Suite 200, Novi, MI 48377 Ph: (248) 347-8191 |
News Archive
University of Limerick researchers have been awarded €175,000 to undertake research which aims to improve diagnosis and management of delirium, dementia and depression among palliative care patients.
Post Co. said Monday it would buy a majority stake in Celtic Healthcare Inc., a closely held provider of hospice and home health care in Pennsylvania and Maryland. Terms of the deal weren't disclosed, although one analyst, Sheryl Skolnick of CRT Capital Group, said average valuations suggests the deal could have been worth at least $50 million. That is a drop in the bucket for Post Co., which has a market capitalization of $2.7 billion.
Vertex Pharmaceuticals (Australia) Pty Ltd., announces the presentation of data from KALYDECO (ivacaftor) studies at the 10th Australasian Cystic Fibrosis Conference in Auckland, New Zealand, August 17 – 20, 2013, which further demonstrate the benefits of the medicine in people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.
Pharmasset, Inc. announced today that the interim results from the PROPEL study conducted by its partner Roche demonstrate that RG7128 triple combination therapy was safe and well tolerated. In that study, the safety profile of RG7128 (1000mg BID or 500mg BID), when administered for 8 or 12 weeks with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin), the standard of care, was similar to the safety profile of SOC alone.
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial. Study AIR645-CS2 is a phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of inhaled AIR645 in suppressing the asthmatic response in subjects with mild asthma. Results are expected in the third quarter of 2010.
› Verified 8 days ago
Dr. James Barry Lesser, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 44000 W 12 Mile Rd, Suite 103, Novi, MI 48377 Phone: 248-347-8290 Fax: 248-305-6845 | |
Usha M Singhi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 26850 Providence Pkwy, Suite 505, Novi, MI 48374 Phone: 248-465-4163 Fax: 248-465-4434 | |
Dr. Serge Alexander Sorser, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 26850 Providence Pkwy, Suite 350, Novi, MI 48374 Phone: 248-662-4110 Fax: 248-662-4120 | |
Mohammad Alhaji, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 39475 Lewis Dr Ste 200, Novi, MI 48377 Phone: 248-471-0675 Fax: 248-254-3874 | |
Dr. Lawrence Livernois Joseph Macdonald, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 44000 W 12 Mile Rd, Suite 113, Novi, MI 48377 Phone: 248-465-9253 Fax: 248-465-9285 | |
Raid Hashim Fadhil Al-khersan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 26850 Providence Pkwy, Suite 505, Novi, MI 48374 Phone: 248-465-4163 Fax: 248-662-4411 |